Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Tomato who wrote (1363)	8/15/2005 10:42:02 PM
From: Jibacoa	Respond to of 3722

Guess one needs one account for trading and another for investing? I find that it's hard to use TA with biotechs that I have fundamental views. Maybe, but if based on your fundamental views on MYGN and with the help of some TA, you had bought it on mid-August last year (after the L at 12.11 when it started to come off from the downtrend coming from its May H at 19.45 ) you would have had a good "entry point" and based on TA would have been able to hold it until the end of the year or perhaps until the end of January 2005 since the stock was able to keep its "uptrend". If you had bought at 14 and sold it at 23 or 24 based on your fundamental views and with the the help of TA you could have made a 70% profit on 4 months (more than 200% annualized.<g>) More recently, the stock gave a "buy signal" in June when it started to come off the downtrend after its June 16 L of 15.06 but the rally to July 21 carried it only to a H of 18.50 which was below its previous attempted rally in May when it had a H of 19 on May 13. So from a TA standpoint, the July 22-July 26 double top at 18.12 told you to "take profits" and wait for further developments as there seems to be a good amount of resistance above the 18 level.<g> The revenues in the last 3Qs have shown some improvement both compared to 2004 and on a sequential basis and the loss also was trimmed somewhat.It also seems likely that the results for the 4thQ should look good compared to last year since in 2004 the revenues were down 4% on the June Q and the expected loss for the Q is around $0.33/shr vs. $0.37/shr in 2004 However, I would rather watch it from the sidelines until the results are released tomorrow.<g>Will see if at the CC they have any further news on Flurizan. bigcharts.marketwatch.com RAGL Bernard